Drug Trial Radar · NCT02527746
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Dec 2012
Primary completion
Dec 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- EVIVE BiotechnologyIndustry
- Sponsor type
- Industry
- Collaborators
- Fudan University
- First posted
- Aug 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients who received up to 4 cycles of Epirubicin and Cyclophosphamide. 18 patients (6 patients each cohort) were assigned to three escalated dose cohorts of 80, 240 and 320 µg/kg.
Conditions
- Neutropenia
- Breast Cancer
Interventions
F-627Drug
F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
EC regimenDrug
Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the Safety of F-627 for Injection in the Treatment of Female Postoperative Patients With Breast Cancer Who Require Adjuvant Chemotherapy.Time frame: Up to 4 cycles (about 84 days)
- Tolerability (Dose-limiting Toxicity) of F-627 for Injection in the Treatment of Female Postoperative Patients With Breast Cancer Who Require Adjuvant Chemotherapy.Time frame: Up to 21 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.